# RAPT Therapeutics Inc. (RAPT)

Source: https://www.quantisnow.com/company/RAPT
Generated: 2026-11-04T13:03:44.421Z

- Ticker: RAPT
- Exchange: NASDAQ
- Sector: Health Care
- Industry: Biotechnology: Pharmaceutical Preparations
- IPO year: 2019
- Website: rapt.com

## About

RAPT Therapeutics, Inc., a clinical-stage immunology-based biopharmaceutical company, focuses on discovering, developing, and commercializing oral small molecule therapies for patients with unmet needs in oncology and inflammatory diseases. Its lead oncology drug candidate is FLX475, an oral small molecule C-C motif chemokine receptor 4 antagonist that is in the Phase 1/2 clinical trial to investigate as a monotherapy and in combination with pembrolizumab in patients with advanced cancer. The company's lead inflammation drug candidate is RPT193 to selectively inhibit the migration of type 2 T helper cells into inflamed tissues. It is also pursuing a range of targets, including general control nonderepressible 2 and hematopoietic progenitor kinase 1 that are in the discovery stage of development. The company was formerly known as FLX Bio, Inc. and changed its name to RAPT Therapeutics, Inc. in May 2019. RAPT Therapeutics, Inc. was incorporated in 2015 and is headquartered in South San Francisco, California.

## Latest RAPT news and filings

- 2026-03-18 13:14 UTC [SEC Form 15-12G filed by RAPT Therapeutics Inc.](https://www.quantisnow.com/insight/sec-form-15-12g-filed-by-rapt-therapeutics-inc-6455882)
- 2026-03-05 14:04 UTC [SEC Form 4] [Director Lyons-Williams Lori closing all direct ownership in the company (SEC Form 4)](https://www.quantisnow.com/insight/director-lyons-williams-lori-closing-all-direct-ownership-in-the-company-6431838)
- 2026-03-05 14:03 UTC [SEC Form 4] [Director Gray Mary Ann closing all direct ownership in the company (SEC Form 4)](https://www.quantisnow.com/insight/director-gray-mary-ann-closing-all-direct-ownership-in-the-6431832)
- 2026-03-05 14:01 UTC [SEC Form 4] [Director Giordano Michael F closing all direct ownership in the company (SEC Form 4)](https://www.quantisnow.com/insight/director-giordano-michael-f-closing-all-direct-ownership-in-the-6431824)
- 2026-03-05 13:59 UTC [SEC Form 4] [Director Dombkowski Ashley L. closing all direct ownership in the company (SEC Form 4)](https://www.quantisnow.com/insight/director-dombkowski-ashley-l-closing-all-direct-ownership-in-the-6431762)
- 2026-03-05 13:58 UTC [SEC Form 4] [CHIEF FINANCIAL OFFICER Young Rodney Kb closing all direct ownership in the company (SEC Form 4)](https://www.quantisnow.com/insight/chief-financial-officer-young-rodney-kb-closing-all-direct-ownership-6431746)
- 2026-03-05 13:56 UTC [SEC Form 4] [CHIEF SCIENTIFIC OFFICER Brockstedt Dirk G. closing all direct ownership in the company (SEC Form 4)](https://www.quantisnow.com/insight/chief-scientific-officer-brockstedt-dirk-g-closing-all-direct-ownership-6431739)
- 2026-03-05 13:55 UTC [SEC Form 4] [PRESIDENT AND CEO Wong Brian Russell closing all direct ownership in the company (SEC Form 4)](https://www.quantisnow.com/insight/president-and-ceo-wong-brian-russell-closing-all-direct-ownership-6431735)
- 2026-03-05 13:53 UTC [SEC Form 4] [Director Kozick Linda closing all direct ownership in the company (SEC Form 4)](https://www.quantisnow.com/insight/director-kozick-linda-closing-all-direct-ownership-in-the-company-6431731)
- 2026-03-05 13:50 UTC [SEC Form 4] [Director Braunstein Scott closing all direct ownership in the company (SEC Form 4)](https://www.quantisnow.com/insight/director-braunstein-scott-closing-all-direct-ownership-in-the-company-6431726)
- 2026-03-05 05:15 UTC [SEC Form EFFECT] [SEC Form EFFECT filed by RAPT Therapeutics Inc.](https://www.quantisnow.com/insight/sec-form-effect-filed-by-rapt-therapeutics-inc-6431219)
- 2026-03-05 05:15 UTC [SEC Form EFFECT] [SEC Form EFFECT filed by RAPT Therapeutics Inc.](https://www.quantisnow.com/insight/sec-form-effect-filed-by-rapt-therapeutics-inc-6431215)
- 2026-03-03 21:23 UTC [SEC Form POS AM filed by RAPT Therapeutics Inc.](https://www.quantisnow.com/insight/sec-form-pos-am-filed-by-rapt-therapeutics-inc-6425498)
- 2026-03-03 21:19 UTC [SEC Form S-8 POS] [SEC Form S-8 POS filed by RAPT Therapeutics Inc.](https://www.quantisnow.com/insight/sec-form-s-8-pos-filed-by-rapt-therapeutics-inc-6425407)
- 2026-03-03 21:18 UTC [SEC Form S-8 POS] [SEC Form S-8 POS filed by RAPT Therapeutics Inc.](https://www.quantisnow.com/insight/sec-form-s-8-pos-filed-by-rapt-therapeutics-inc-6425406)
- 2026-03-03 21:21 UTC [SEC Form POS AM filed by RAPT Therapeutics Inc.](https://www.quantisnow.com/insight/sec-form-pos-am-filed-by-rapt-therapeutics-inc-6425404)
- 2026-03-03 21:17 UTC [SEC Form S-8 POS] [SEC Form S-8 POS filed by RAPT Therapeutics Inc.](https://www.quantisnow.com/insight/sec-form-s-8-pos-filed-by-rapt-therapeutics-inc-6425347)
- 2026-03-03 21:15 UTC [SEC Form S-8 POS] [SEC Form S-8 POS filed by RAPT Therapeutics Inc.](https://www.quantisnow.com/insight/sec-form-s-8-pos-filed-by-rapt-therapeutics-inc-6425335)
- 2026-03-03 21:14 UTC [SEC Form S-8 POS] [SEC Form S-8 POS filed by RAPT Therapeutics Inc.](https://www.quantisnow.com/insight/sec-form-s-8-pos-filed-by-rapt-therapeutics-inc-6425255)
- 2026-03-03 21:12 UTC [SEC Form S-8 POS] [SEC Form S-8 POS filed by RAPT Therapeutics Inc.](https://www.quantisnow.com/insight/sec-form-s-8-pos-filed-by-rapt-therapeutics-inc-6425248)
- 2026-03-03 21:11 UTC [SEC Form S-8 POS] [SEC Form S-8 POS filed by RAPT Therapeutics Inc.](https://www.quantisnow.com/insight/sec-form-s-8-pos-filed-by-rapt-therapeutics-inc-6425175)
- 2026-03-03 21:09 UTC [SEC Form S-8 POS] [SEC Form S-8 POS filed by RAPT Therapeutics Inc.](https://www.quantisnow.com/insight/sec-form-s-8-pos-filed-by-rapt-therapeutics-inc-6425131)
- 2026-03-03 14:14 UTC [SEC Form 25-NSE filed by RAPT Therapeutics Inc.](https://www.quantisnow.com/insight/sec-form-25-nse-filed-by-rapt-therapeutics-inc-6424200)
- 2026-03-03 14:02 UTC [SEC Form 8-K] [RAPT Therapeutics Inc. filed SEC Form 8-K: Completion of Acquisition or Disposition of Assets, Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Material Modification to Rights of Security Holders, Changes in Control of Registrant, Leadership Update](https://www.quantisnow.com/insight/rapt-therapeutics-inc-filed-sec-form-8-k-completion-of-acquisition-6424176)
- 2026-03-03 11:05 UTC [SEC Schedule 14D-9] [Amendment: SEC Form SC 14D9/A filed by RAPT Therapeutics Inc.](https://www.quantisnow.com/insight/amendment-sec-form-sc-14d9a-filed-by-rapt-therapeutics-inc-6423626)
- 2026-03-03 11:04 UTC [SEC Schedule TOT] [Amendment: SEC Form SC TO-T/A filed by RAPT Therapeutics Inc.](https://www.quantisnow.com/insight/amendment-sec-form-sc-to-ta-filed-by-rapt-therapeutics-inc-6423614)
- 2026-02-24 11:08 UTC [SEC Schedule TOT] [Amendment: SEC Form SC TO-T/A filed by RAPT Therapeutics Inc.](https://www.quantisnow.com/insight/amendment-sec-form-sc-to-ta-filed-by-rapt-therapeutics-inc-6408558)
- 2026-02-24 11:01 UTC [SEC Schedule 14D-9] [Amendment: SEC Form SC 14D9/A filed by RAPT Therapeutics Inc.](https://www.quantisnow.com/insight/amendment-sec-form-sc-14d9a-filed-by-rapt-therapeutics-inc-6408533)
- 2026-02-17 13:45 UTC [Amendment: SEC Form SCHEDULE 13G/A filed by RAPT Therapeutics Inc.](https://www.quantisnow.com/insight/amendment-sec-form-schedule-13ga-filed-by-rapt-therapeutics-inc-6394672)
- 2026-02-09 21:53 UTC [SEC Form SCHEDULE 13G filed by RAPT Therapeutics Inc.](https://www.quantisnow.com/insight/sec-form-schedule-13g-filed-by-rapt-therapeutics-inc-6382220)
- 2026-02-02 22:58 UTC [SEC Form 4] [Director Braunstein Scott was granted 4,956 shares (SEC Form 4)](https://www.quantisnow.com/insight/director-braunstein-scott-was-granted-4956-shares-sec-form-4-6370684)
- 2026-02-02 22:56 UTC [SEC Form 4] [Director Giordano Michael F was granted 4,956 shares (SEC Form 4)](https://www.quantisnow.com/insight/director-giordano-michael-f-was-granted-4956-shares-sec-form-6370682)
- 2026-02-02 22:53 UTC [SEC Form 4] [Director Gray Mary Ann was granted 4,956 shares (SEC Form 4)](https://www.quantisnow.com/insight/director-gray-mary-ann-was-granted-4956-shares-sec-form-6370679)
- 2026-02-02 22:47 UTC [SEC Form 4] [Director Lyons-Williams Lori was granted 4,956 shares (SEC Form 4)](https://www.quantisnow.com/insight/director-lyons-williams-lori-was-granted-4956-shares-sec-form-4-6370669)
- 2026-02-02 22:45 UTC [SEC Form 4] [Director Kozick Linda was granted 4,956 shares (SEC Form 4)](https://www.quantisnow.com/insight/director-kozick-linda-was-granted-4956-shares-sec-form-4-6370664)
- 2026-02-02 22:38 UTC [SEC Form 4] [Director Dombkowski Ashley L. was granted 4,956 shares (SEC Form 4)](https://www.quantisnow.com/insight/director-dombkowski-ashley-l-was-granted-4956-shares-sec-form-6370641)
- 2026-02-02 13:33 UTC [SEC Schedule 14D-9] [SEC Form SC 14D9 filed by RAPT Therapeutics Inc.](https://www.quantisnow.com/insight/sec-form-sc-14d9-filed-by-rapt-therapeutics-inc-6369251)
- 2026-02-02 11:42 UTC [SEC Schedule TOT] [SEC Form SC TO-T filed by RAPT Therapeutics Inc.](https://www.quantisnow.com/insight/sec-form-sc-to-t-filed-by-rapt-therapeutics-inc-6368799)
- 2026-01-20 21:05 UTC [SEC Form SC TO-C filed by RAPT Therapeutics Inc.](https://www.quantisnow.com/insight/sec-form-sc-to-c-filed-by-rapt-therapeutics-inc-6354036)
- 2026-01-20 19:13 UTC [Forbion Announces Second Exit from Forbion Growth Fund III Following $2.2 Billion Acquisition of RAPT Therapeutics by GSK](https://www.quantisnow.com/insight/forbion-announces-second-exit-from-forbion-growth-fund-iii-following-6353878)

## More

- Live page with ratings, short volume, options and peers: https://www.quantisnow.com/company/RAPT
- Earnings history: https://www.quantisnow.com/earnings/RAPT
- Dividend history: https://www.quantisnow.com/dividends/RAPT
- Insider transactions: https://www.quantisnow.com/insiders/RAPT
- Options chain: https://www.quantisnow.com/options/RAPT
- SEC 8-K filings only: https://www.quantisnow.com/company/RAPT/8-k
- RSS and alerts for RAPT: https://www.quantisnow.com/docs/rss-feeds.md